Mazen Hanna Formal Picture.jpg

Mazen Hanna, Ph.D. (President and BoD)  currently serves as the President of the Company and vice President for Drug development.  Previosuly, he served asthe co-founder of Bradford Particle Design plc (acquired by Inhale Therapeutic Systems, Inc. also known as Nektar Therapeutics) where he invented and led the development of the novel particle design technology SEDS (Solution Enhanced Dispersion by Supercritical Fluids) from 1995 to 2004. Dr. Hanna served as Director and Chief Scientific Officer of Thar Pharma Limited from 2006 to 2011. Dr. Hanna holds a Ph.D. in pharmaceutical technology from the University of Bradford (UK). 

Bernard Skerkowski picture.jpg
Santosh Mishra picture.jpg

Bernard Skerkowski, CPA (Vice President, Finance) has over 25 years of accounting experience in both the private and public sector, ranging from the banking industry to government auditing and from public practice to small business administration. He has been a Certified General Accountant since 1983 and has operated his own private practice for the past 12 years. He has practiced in both the US and Canada and is a Certified Tax Advisor with the IRS

Santosh K Mishra, PhD (Vice President, Operations and Director of Personalized Medicine) has extensive R&D expertise in discovery and validation of drug targets and/or diagnostics that have resulted in commercial products. He has expertise in evaluating and understanding genomic, genetic, and epigenetic effects on diseases of aging, cancer, and immunology. He has executive-level management experience in multinational companies including as a Principal Scientist, Advanced Technology for Genetics (GlaxoSmithKline), as Managing Director, Lilly Systems Biology (Eli Lilly and Company), as an Executive Director, Bioinformatics Institute, BMRC, Singapore, Executive Vice President, R&D,  Reddy’s Lab, India and President of Kever Pharma, India; and most recently as the Director Bioinformatics & Co-Director Collaborative Genome Center(CGC), VGTI Florida. He has directed successfully innovative, start-up and global operations in public/business/government sectors.

Chandresh Saraiya picture.png

Chandresh Saraiya, MD(VP, Medical affairs) Dr. Saraiya previously served as chairman, CEO and most recently medical director and vice president of Global Business Development for Nanotech Diagnostics and Therapeutics Inc. (NDT), a startup and privately held clinical research company located in Tampa, FL. Dr. Saraiya spearheads the clinical testing of the FiSS platform, especially for its use for personalized cancer testing.

Sagar picture.jpg

Sagar Galwankar, MD, MPH (Vice President, Marketing & Global Operations) did his MD in Internal Medicine (Infectious diseases) in India and has MPH degree from USF. He has been associated with TGN as an investor for several years. Dr. Galwankar brings to Transgenex his biotech experience in India, where he served as the Managing Director of the Nanodiagnostics Private Limited, India during 2009-2011. The company is involved in creating solutions for point-of-care diagnosis of medical conditions and devising better drug delivery system geared towards novel therapeutic targets.